Quick answer
Some specific peptide or peptide-related drugs are FDA-approved for specific uses. Many substances marketed online as peptides are not approved, and compounded products are not FDA-approved. Check the exact product and labeling in an official FDA database rather than applying one answer to the entire category.
Key takeaways
- ✓Approval belongs to a specific product and labeled use.
- ✓Off-label prescribing does not erase an approved product’s status, but the off-label use itself is not FDA-approved.
- ✓Compounded and investigational products require separate descriptions.
- ✓Category-wide claims such as “peptides are FDA-approved” are misleading.
01
There is no single yes-or-no answer for a broad category
Approval applies to a specific product and labeled use, not to the marketing category “peptides” as a whole. Search the exact product in Drugs@FDA and review its current labeling.
02
Keep the classifications separate
An FDA-approved product, an approved product prescribed off-label, a compounded drug, and an investigational or unapproved substance are different classifications. A provider’s marketing page does not change a product’s regulatory status.
03
How to check a product
Write down the exact active ingredient, brand name if any, dosage form, route, manufacturer or compounder, and proposed use. Search Drugs@FDA and review the current prescribing information. If the product cannot be matched, ask the clinician to explain its regulatory classification and supporting source.
Do not rely on a familiar molecule name alone. Salt forms, combinations, concentrations, routes, and compounded preparations may differ from an approved product.
04
Four classifications consumers often confuse
An approved drug used according to its label, an approved drug prescribed off-label, a compounded drug, and an investigational or unapproved substance are distinct. Off-label prescribing can be lawful medical practice, but marketing should not imply that FDA evaluated and approved the unapproved use.
Compounded products are also not approved even when they contain an ingredient found in an approved product. FDA has specifically warned that some semaglutide salt forms differ from the active ingredient used in approved drugs.
05
Peptides FDA has flagged for potential compounding risks
FDA maintains safety-risk information for certain bulk substances, including several names commonly promoted in peptide markets. The agency notes limited human safety information, immunogenicity concerns, impurity and characterization challenges, or reported serious events for various substances. The list and regulatory policies can change, so date every classification.
Common questions
Frequently asked questions
Are all peptides unapproved?
No. Some specific peptide or peptide-related drug products are FDA-approved. The answer must be product-specific.
Is BPC-157 FDA-approved?
FDA’s safety-risk page discusses BPC-157 as a bulk substance that may present significant safety risks in compounding and notes limited safety information; it is not an FDA-approved drug product.
Where can I check FDA approval?
Search the exact product in Drugs@FDA and review its current labeling. Ask a clinician or pharmacist when the formulation is unclear.
Primary sources
- About Drugs@FDAU.S. Food and Drug Administration · checked July 20, 2026
- Compounding and the FDA: Questions and AnswersU.S. Food and Drug Administration · checked July 20, 2026
- Certain Bulk Drug Substances That May Present Significant Safety RisksU.S. Food and Drug Administration · checked July 20, 2026